PET/CT Imaging in Cardiac Sarcoidosis

被引：0
作者：
Sobic-Saranovic D. [1 ,2 ]
Artiko V. [1 ,2 ]
Obradovic V. [1 ,2 ]
机构：
[1] Faculty of Medicine, University of Belgrade, Belgrade
[2] Center of Nuclear Medicine, PET Center, Clinical Center of Serbia, Visegradska 26, Belgrade
来源：
Current Cardiovascular Imaging Reports | 2015年 / 8卷 / 1期
关键词：
18 F-fluorodeoxyglucose; Assessment of disease activity; Cardiac sarcoidosis; Monitoring the effect of immunosuppressive therapy; Patient preparation for glucose uptake suppression in myocardium; PET/CT; Prognostic assessment of cardiac sarcoidosis;
D O I：
10.1007/s12410-014-9305-x
中图分类号：
学科分类号：
摘要：
Cardiac sarcoidosis (CS) is a potentially life-threatening disease, but diagnosing CS remains a challenge because of nonspecific clinical manifestations and significant proportion of asymptomatic patients. Also, there is no standardized work-up for early diagnosis and management of CS. In recent years, there has been increasing interest in the use of advanced imaging modalities for evaluation of CS, including cardiac magnetic resonance imaging (MRI) and positron emission tomography with 18f-fluorodeoxyglucose (FDG PET) integrated with computed tomography (PET/CT). The purpose of this review is to highlight the utility of PET/CT for diagnosis and management of CS. The advantage of PET/CT is that it can detect FDG accumulation in the activated inflammatory cells, allowing visualization of active sites and early diagnosis of CS. Special emphasis has been put toward the development of appropriate preparation protocols that minimize physiological FDG uptake in the myocardium and optimal imaging protocols that allow sensitive and accurate detection of CS. Aside from early diagnosis, FDG PET/CT may inform when to start the therapy and whether the patient responded to treatment. FDG PET/CT may also be useful for follow-up and risk assessment of patients with CS. The limitations of FDG PET/CT are discussed with respect to a radiation exposure and control of glucose metabolism and insulin levels to avoid nonspecific myocardial uptake of FDG. Despite the progress made, more studies are needed to further refine clinical applications of FDG PET/CT in patients with CS. © 2014, Springer Science+Business Media New York.
引用
收藏
页码：1 / 9
页数：8
相关论文
共 80 条
  • [11] Sobic-Saranovic D., Grozdic I., Videnovic-Ivanov J., Et al., Responsiveness of FDG PET/CT to treatment of patients with active chronic sarcoidosis, Clin Nucl Med, 38, pp. 516-521, (2013)
  • [12] Mostard R.L.M., Voo S., van Kroonenburgh M.J., Et al., Inflammatory activity assessment by F18 FDG-PET/CT in persistent symptomatic sarcoidosis, Respir Med, 105, pp. 1917-1924, (2011)
  • [13] Teirstein A.S., Machac J., Almeida O., Et al., Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis, Chest, 132, pp. 1949-1953, (2007)
  • [14] Mostard R.L.M., Varschakelen J.A., van Kroonenburgh M.J., Et al., Severity of pulmonary involvement and 18 F-FDG PET activity in sarcoidosis, Respir Med, 107, pp. 439-447, (2013)
  • [15] Ambrosini V., Zompatori M., Fasano L., Et al., 18 F-FDG PET/CT for the assessment of disease extension and activity in patients with sarcoidosis. Results of preliminary prospective study, Clin Nucl Med, 38, pp. e171-e177, (2013)
  • [16] Mostard R.L., Prompers L., Weijers R.E., Et al., F-18 FDG PET/CT for detecting bone and bone marrow involvement in sarcoidosis patients, Clin Nucl Med, 37, pp. 21-25, (2012)
  • [17] Jain V., Hasselquist S., Delaney M., PET scanning in sarcoidosis, Ann NY Acad Sci, 1228, pp. 46-58, (2011)
  • [18] Sobic-Saranovic D., Artiko V., Obradovic V., FDG PET Imaging in Sarcoidosis, Semin Nucl Med, 43, pp. 404-411, (2013)
  • [19] Treglia G., Annunziata S., Sobic-Saranovic D., Et al., The role of 18 F-FDG-PET and PET/CT in patients with sarcoidosis: an updated evidence-based reviewed, Acad Radiol, 21, pp. 675-684, (2014)
  • [20] Mochizuk T., Tsukamoto E., Kuge Y., Et al., FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models, J Nucl Med, 42, pp. 1551-1555, (2001)
12345678